RO7851624 in relapsed/refractory multiple myeloma (RRMM)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial will assess the safety, how the drug moves in the body, and preliminary activity of RO7851624 in adults with relapsed/refractory multiple myeloma who have been exposed to PI, IMiD, and anti-CD38 therapies. Eligible participants have good performance status, measurable disease, and a life expectancy of at least 12 weeks. The study will exclude individuals with recent incompatible chemotherapy, autologous or allogeneic stem cell transplants, or solid organ transplants. The research is led by Genentech, with sites at Peter MacCallum Cancer Centre in Australia and Samsung Medical Center in South Korea.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Life expectancy of at least 12 weeks.
* Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
* Measurable disease.

Exclusion Criteria:

* Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) with insufficient washout prior to first dose of study treatment.
* Autologous stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.
* Prior allogeneic SCT.
* Prior solid organ transplantation.

Where it's running

• Peter MacCallum Cancer Center
  Parkville, Victoria, Australia Recruiting
• Samsung Medical Center
  Gangnam-gu, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Reference Study ID Number: GO46140 https://forpatients.roche.com/ No attachments to email below.
• Email: global-roche-genentech-trials@gene.com
• Phone: 888-662-6728 (U.S. and Canada)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CT0596 CAR-T in relapsed/refractory multiple myeloma: a phased dose-find and efficacy study

  This study tests CT0596 CAR-T cells in adults with relapsed/refractory multiple myeloma who have already had multiple prior treatments.

  Recruiting Phase 1/2 UCARsgen Biotech Limited · Suzhou, Jiangsu and 1 other locations · NCT07760454

• KMA-targeted CAR T-cells for relapsed/refractory kappa-restricted multiple myeloma

  This study tests escalating doses of a patient’s own PMCC-COE-KMA CAR T-cells to see if they are safe and effective for relapsed/refractory kappa-restricted multiple myeloma expressing KMA.

  Recruiting Phase 1 Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria · NCT07541391

• IL-15–armored CAR-T for relapsed or refractory multiple myeloma and plasma cell leukemia

  This trial will test IL-15–armored CAR-T cell therapy to see if it helps adults with relapsed or refractory multiple myeloma or plasma cell leukemia, including those with persistent or returning MRD.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07509086

• IMV102 treatment for relapsed or refractory multiple myeloma

  This trial will try a single infusion of IMV102 in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies to see if it is safe and helps control the cancer.

  Recruiting Early Phase 1 Suzhou Immunofoco Biotechnology Co., Ltd · Beijing and 3 other locations · NCT07493135

• See if SG2918 is safe for adults with relapsed/refractory multiple myeloma

  This study tests SG2918 in adults with relapsed or refractory multiple myeloma to see if it is safe and tolerable.

  Recruiting at 4 sites Phase 1/2 Hangzhou Sumgen Biotech Co., Ltd. · Zhengzhou, Henan and 3 other locations · NCT07454187

• Cemsidomide plus dexamethasone for relapsed or refractory multiple myeloma

  This will try cemsidomide with dexamethasone to see if it works and is safe for adults with relapsed or refractory multiple myeloma who have had several prior treatments.

  Recruiting at 33 sites Phase 2 C4 Therapeutics, Inc. · Huntsville, Alabama and 59 other locations · NCT07284758

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.